Epizyme, Inc. (NASDAQ:EPZM) insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total transaction of $235,200.00. Following the completion of the transaction, the insider now owns 22,228 shares in the company, valued at approximately $348,535.04. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Peter Tai-Ching Ho also recently made the following trade(s):

  • On Monday, July 24th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00.
  • On Monday, June 26th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $14.87, for a total transaction of $223,050.00.

Shares of Epizyme, Inc. (NASDAQ:EPZM) opened at 17.10 on Thursday. The stock has a 50 day moving average of $13.73 and a 200-day moving average of $14.67. Epizyme, Inc. has a 52 week low of $7.02 and a 52 week high of $18.50. The firm’s market cap is $999.77 million.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The business had revenue of $10 million during the quarter, compared to analysts’ expectations of $3.95 million. During the same quarter in the prior year, the business posted ($0.49) earnings per share. Epizyme’s revenue was up 2027.7% compared to the same quarter last year. Equities research analysts expect that Epizyme, Inc. will post ($2.39) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Epizyme, Inc. (EPZM) Insider Sells $235,200.00 in Stock” was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/epizyme-inc-epzm-insider-sells-235200-00-in-stock/1533383.html.

A number of large investors have recently bought and sold shares of the company. Palo Alto Investors LLC boosted its stake in Epizyme by 18.9% in the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after buying an additional 907,245 shares in the last quarter. Vanguard Group Inc. boosted its stake in Epizyme by 6.2% in the second quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after buying an additional 200,982 shares in the last quarter. State Street Corp boosted its stake in Epizyme by 59.6% in the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after buying an additional 658,727 shares in the last quarter. Foresite Capital Management II LLC boosted its stake in Epizyme by 1.1% in the first quarter. Foresite Capital Management II LLC now owns 1,543,118 shares of the biopharmaceutical company’s stock valued at $26,464,000 after buying an additional 16,481 shares in the last quarter. Finally, Foresite Capital Management III LLC boosted its stake in Epizyme by 12.7% in the first quarter. Foresite Capital Management III LLC now owns 681,922 shares of the biopharmaceutical company’s stock valued at $11,695,000 after buying an additional 76,683 shares in the last quarter. 83.74% of the stock is owned by institutional investors and hedge funds.

EPZM has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Oppenheimer Holdings, Inc. set a $26.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a report on Monday, June 5th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Tuesday, May 16th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Epizyme in a research note on Wednesday, June 7th. Finally, Royal Bank Of Canada set a $20.00 target price on shares of Epizyme and gave the company a “buy” rating in a research note on Monday, June 12th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Epizyme has an average rating of “Buy” and an average target price of $23.38.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.